Unichem Laboratories Ltd.

₹366.9

-9.9 (-2.6%)

UNICHEMLAB Share Price

Pharmaceuticals & Biotechnology

As on April 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,600 Cr

P/E Ratio18.78

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	374.29	Bearish
10-DMA	360.85	Bullish
20-DMA	336.54	Bullish
50-DMA	337.38	Bullish
100-DMA	380.4	Bearish
200-DMA	447.39	Bearish

Historical Performance

1 Year

-40.7%

3 Years

-3.3%

5 Years

5.1%

10 Years

47.3%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	21,110	17,851	13,430	12,698	12,351
Total Expenditure	18,461	16,982	13,886	11,970	11,440
Other Income	353	316	385	475	502
Operating Profit	3,002	1,185	-70	1,203	1,413
Interest	210	227	173	61	51
Depreciation	1,246	1,232	1,134	912	844
Profit Before Tax	1,546	-850	-1,764	220	515
Consolidated Net Profit	1,375	-938	-2,022	331	343
Adjusted EPS	20	-13	-29	5	5

Compounded Sales Growth

10 Years:11.9

5 Years:13.8

3 Years:10.7

TTM:3.4

Compounded Profit Growth

10 Years:12.8

5 Years:-4.6

3 Years:33

TTM:-12.7

Stock Price CAGR

10 Years:4.1

5 Years:1.5

3 Years:-1.1

TTM:-40.1

Return on Equity

10 Years:11.9

5 Years:4.9

3 Years:-28.7

last year:19.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	141	141	141	141	141
Total Reserves	24,314	24,212	24,092	25,936	25,350
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	987	923	1,080	1,439	492
Other Current Liabilities	1,072	930	1,283	1,351	1,770
Short Term Borrowings	3,403	1,553	2,081	2,157	1,006
Total Liabilities	35,436	32,682	31,829	33,144	31,118
Capital Work in Progress	307	1,227	1,475	4,938	5,675
Long Term Loans & Advances	1,506	1,249	1,681	1,656	1,129
Currents Investments	---	13	15	2,636	2,364
Short Term Loans and Advances	1,016	1,755	1,564	1,381	2,138
Total Current Assets	20,295	17,433	15,885	16,449	13,773
Total Assets	35,436	32,682	31,829	33,144	31,118
Adjusted Book Value	347	346	344	370	362

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 18.78, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -1.2%, indicating poor shareholder returns.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹3002 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹21110 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 599411.9

No. of Shares: 1634 (Approx)

Performance:-40.1%

P/L: ₹-400588.1

NIFTY Performance: -1.4%

1 day Top Gainers